Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A £210,000 donation from the Alan Davidson Foundation has been made to our Department to advance our world-leading research into Motor Neuron Disease. The funding will support a project manager to deliver an innovative research project using the genetic causes of MND to develop approaches to early diagnosis.

Alan Davidson with dog and letter

MND symptoms develop insidiously and the early stages can be similar to other conditions, which means that diagnosis can sometimes take a year or more. As a result, damage to the nervous system can go undetected before physical symptoms become apparent. Professor Talbot and his research group work as part of the Oxford Motor Neuron Disease Centre, linking the research to clinical care.

The team has already established promising approaches to treatment in patients who currently have the disease. The aim of this new ground-breaking research is to identify people at risk of MND before symptoms occur, so that treatment can be applied at the early stages when it can be more effective and disability can be prevented.

About 10 per cent of patients with MND have a genetic mutation and each of their close relatives (parents, siblings and children) will have a 50 per cent chance of carrying the gene that leads to MND. The research funded by ADF will sign up 300–400 'at risk' individuals, who will be carefully monitored to enable the team to pick up the very earliest signals of the disease. The ultimate aim is to produce a blood test that could be used in general practice to screen for the silent damage occurring in the early phase of MND. A cohort study of this kind, linking in with the established MND network, will be unique, and once the cohort is in place, major research funding will also be sought to analyse the samples donated by people taking part in the study.

I remember Alan vividly. He was an exceptional individual who achieved great things in his life and his enquiring mind lives on in the foundation's commitment to MND research. This pioneering new project aims to understand the very earliest changes that occur, before physical symptoms progress. In the longer term it will contribute towards our aim of making MND a preventable condition.
- Professor Kevin Talbot

Alan Hayes Davidson RIBA was a Scottish architectural visualiser who pioneered the use of computers to create realistic digital images of buildings. Having started his career as an architect, he founded the world-leading visualisation studio Hayes Davidson in 1989 to pursue his interest in computer modelling, making it the first company dedicated to producing computer-generated imagery for the architecture industry. The studio was commissioned to illustrate many well-known and iconic London buildings before they were built or extended, including the London Eye, the Tate Modern, the Millennium Dome (now the O2), the Royal Academy, the Royal Festival Hall and the British Museum.

Alan was diagnosed with MND in 2012 and the Alan Davidson Foundation was set up in 2015, three years before his death at the age of 58. He committed the majority of his estate to good causes through the foundation, including MND research.

Caite Healy, ADF Trustee and friend of Alan, says: 'During his own illness, Alan was hugely helped by understanding the in-depth science behind the treatment options. When he set up the Alan Davidson Foundation, he wanted his legacy to support innovative science and new ideas. We know he would have been hugely enthusiastic about this exciting project and what it aims to achieve.'

Make a Gift

If you would like to make a gift to the Oxford Motor Neuron Disease Centre, please visit the University of Oxford Development Office donation page.

Similar stories

Bioelectronic implant offers an intelligent therapy to treat incontinence

The first participants in a clinical trial of a bioelectrical therapy to treat incontinence have received their 'smart' bioelectronic implants.

Direct evidence of reduced NMDA receptors in people with form of encephalitis

NMDAR-antibody encephalitis is an autoimmune brain condition caused by patient’s own antibodies that bind to NMDA (N-Methyl-D-Aspartate) receptors in the synapses between nerve cells.

Director of MRC Brain Network Dynamics Unit appointed

From 2 January 2023, Professor Peter Magill will lead the Medical Research Council Brain Network Dynamics Unit (MRC BNDU) at the University of Oxford.

Study reveals association between diagnosis of a neuropsychiatric condition and severe outcome from COVID-19 infection, and other severe acute respiratory infections

New research from the University of Oxford has shown an increased risk of severe illness and death from both COVID-19 and other severe respiratory infections, such as influenza and pneumonia, among people with a pre-existing mental health condition.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.